A Phase 3 Efficacy Study Of Dimebon In Patients With Moderate To Severe Alzheimer's Disease

Stopped early · Phase 3 · Has a placebo group

Conditions studied: Alzheimer Disease

In brief

No Dimebon clinical data exist yet in patients with disease that has advanced to the moderate-to-severe stage. Therefore, this study evaluates the safety and efficacy of Dimebon in patients with moderate-to-severe AD who are receiving existing background therapy with memantine.

Key facts

Study ID

NCT00912288

Run by

Pfizer

People needed

86

Starts

2009-09-01

Expected to finish

2010-08-01

Last updated by the study team

2012-10-02

Who can join

Age: 50 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Are men and women ≥ 50 years of age with a diagnosis of Alzheimers disease.
• Have a Mini-Mental State Exam between 5 and 14 inclusive.
• Have been taking the medication memantine (ie., Namenda) for at least six months prior to this study.
• Must have a caregiver who assists the patient at least five days per week for at least three hours per day, who can accompany patient to study visits, and who has an intimate knowledge of the patient's health states and personal care.

You may not qualify if…

• Have taken medicines for Alzheimers disease other than memantine (e.g., donepezil, rivastigmine, galantamine, tacrine) within 2 months prior to this study.
• Dementia other than Alzheimers disease.
• Any medical condition or reason that interferes with the ability of the patient to participate in or complete the trial or places the patient at undue risk, as judged by the study doctor.

Where it is running

• Pfizer Investigational Site — Phoenix, Arizona, United States
• Pfizer Investigational Site — Costa Mesa, California, United States
• Pfizer Investigational Site — Encino, California, United States
• Pfizer Investigational Site — Los Alamitos, California, United States
• Pfizer Investigational Site — Newport Beach, California, United States
• Pfizer Investigational Site — Newport Beach, California, United States
• Pfizer Investigational Site — Denver, Colorado, United States
• Pfizer Investigational Site — New Haven, Connecticut, United States
• Pfizer Investigational Site — Brooksville, Florida, United States
• Pfizer Investigational Site — Delray Beach, Florida, United States
• Pfizer Investigational Site — West Palm Beach, Florida, United States
• Pfizer Investigational Site — Indianapolis, Indiana, United States
• Pfizer Investigational Site — Lexington, Kentucky, United States
• Pfizer Investigational Site — Pittsfield, Massachusetts, United States
• Pfizer Investigational Site — Princeton, New Jersey, United States
• Pfizer Investigational Site — Rochester, New York, United States
• Pfizer Investigational Site — Syracuse, New York, United States
• Pfizer Investigational Site — Norristown, Pennsylvania, United States
• Pfizer Investigational Site — East Providence, Rhode Island, United States
• Pfizer Investigational Site — Cordova, Tennessee, United States
• Pfizer Investigational Site — Middleton, Wisconsin, United States
• Pfizer Investigational Site — Winnipeg, Manitoba, Canada
• Pfizer Investigational Site — Montreal, Quebec, Canada
• Pfizer Investigational Site — Québec, Quebec, Canada
• Pfizer Investigational Site — Berlin, Germany

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.